Introduction {#Sec1}
============

Critical limb ischemia (CLI) due to peripheral arterial disease is a condition in which the lower extremity is threatened and is defined by ischemic rest pain, with or without ischemic tissue loss \[[@CR1]\]. CLI has a great impact on healthcare and associated healthcare budget \[[@CR2]\]. A number of risk factors are known to be associated with the development of CLI, which are diabetes mellitus, smoking, increased age, lipid abnormalities and low ankle-brachial pressure index \[[@CR2]\].

Of the CLI patients, 10--40% will lose their leg within 6 months and the 1-year mortality rate is 25% in CLI patients who are not able to be revascularized \[[@CR2]--[@CR4]\].

Percutaneous transluminal angioplasty (PTA), with or without stenting, is an alternative approach to surgical bypass as a revascularization method in patients with CLI \[[@CR5], [@CR6]\]. Compared to surgery, it involves advantages such as minimal access trauma and shorter hospital stay. Therefore, PTA is more suited and often suggested as first-line therapy for high-risk CLI patients with a lower life expectancy \[[@CR7]--[@CR10]\].

To identify the effect of PTA, clinical outcomes such as wound healing, amputation free survival (AFS) and survival during follow-up are recorded and presented \[[@CR11]--[@CR17]\]. However, interpreting these clinical outcomes in this patient group is difficult, because of its heterogeneity in the risk factors such as comorbid diabetes, difference in age, renal failure or lifestyle factors such as smoking and obesity. We often see a discrepancy between a good revascularization result of the PTA, identified on digital subtraction angiography (DSA) and an unexpected poor clinical outcome with early amputation \[[@CR9], [@CR18], [@CR19]\]. For future analysis of study results concerning endovascular treatment in CLI patients, it is important to identity which risk factors are associated with poor outcome.

Therefore, the aim of this systematic review was to identify risk factors in predicting poor clinical outcome in patients with CLI undergoing PTA with or without stenting. Drug eluting technologies were not included in the review to try to maintain homogeneity in the study population.

Materials and Methods {#Sec2}
=====================

This review was conducted according to the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines \[[@CR20]\]. The review protocol was not published or registered in advance.

Search Strategy {#Sec3}
---------------

An electronic search was performed in the databases PubMed and EMBASE for studies analyzing CLI and clinical outcome after percutaneous revascularization. The search period was from January 2006 to April 2017. Search terms used for PubMed and EMBASE are listed below.

*PubMed* **"**Critical limb ischemia OR critical limb ischemia AND (angioplasty OR endovascular revascularization OR percutaneous intentional extraluminal revascularization OR subintimal OR endovascular therapy) AND (major amputation OR amputation free survival OR death OR ulcer healing OR wound healing OR mortality OR survival) AND Humans".

*Embase*: (Critical limb ischamia OR critical limb ischemia) AND (percutaneous transluminal angioplasty balloon OR percutaneous transluminal angioplasty OR angioplasty OR stent OR revascularization) AND mortality OR (amputation OR major amputation OR leg amputation) OR (ulcer healing OR wound healing) OR (survival).

Study Selection {#Sec4}
---------------

### Step 1 {#FPar1}

All retrieved articles were checked on title and abstract by one observer (X2). Duplicates, reviews, guidelines, comments, letters to the editor, conferences, case reports, study protocol and articles not containing CLI were excluded.

### Step 2 {#FPar2}

All remaining articles were also checked on abstract by the same observer (X2). When studies contained less than fifty patients, patients did not receive PTA, the study was retrospective (we considered prospective database as prospective study) or the follow-up period was less than 1 year, these studies were excluded. To avoid exclusion of relevant articles, ambiguous articles were retrieved as full text and treated as potentially eligible articles. The observer double-checked step 2 and was not blinded to author and journal names.

Inclusion of Relevant Articles {#Sec5}
------------------------------

Three observers (X1, X2 and X3) independently checked all remaining articles for inclusion and exclusion criteria. Two observers (X1 and X2) each checked half of the relevant articles, and the findings were discussed with observer 3 (X3) who has experience on data extraction of 25 meta-analyses.

The inclusion criteria were as follows: (1) prospective study or prospective database (we considered prospective database as prospective study, hospital billing and other registries as retrospective); (2) patients with CLI as defined by Fontaine class III--IV or Rutherford class IV--VI (rest pain, non-healing ulcer or gangrene); (3) patients underwent (regular) PTA (no drug eluting stents); (4) \>50 patients with CLI undergoing PTA; (5) data on outcome were available for at least 1 year of follow-up (outcomes were healing, AFS (major of minor) and overall survival); (6) separate data on CLI and PTA were available (in studies that included a variety of patients or treatments, for example data on CLI patient who underwent PTA or bypass surgery); and (7) finally, data on predictive factors were reported. Exclusion criterion was duplicate data.

Data Extraction {#Sec6}
---------------

Two reviewers (X1, radiologist with experience in extracting data of two reviews and X2, medical student) used a standardized form to extract data independently on study design characteristics, patient selection, baseline patient characteristics, procedure description, angiographic outcomes and complications, follow-up and dropout patients, clinical outcomes and predictive factors. Again, each observer extracted data of half of the articles and were double-checked by the third reviewer with experience on data extraction of 25 meta-analyses.

*Study design characteristics* The following data on study design characteristics were extracted: (1) study type (cohort, part of RCT or other); (2) study design (single center or multicenter and prospective study or prospective database retrospectively analyzed); (3) setting initiation institute (academic, tertiary or other); (4) department initiation by first author (radiology, surgery or other); (5) period of recruitment; (6) institutional review board approval (approved and informed consent obtained/waived, not approved or unclear); and (7) funding or a potential role of funders in the study (conflict of interest).

*Patient selection* The following data on patient selection were retrieved: (1) consecutive sample of patients enrolled (yes or no); (2) inclusion and exclusion criteria defined; and (3) spectrum of patients representative for CLI patients normally receiving PTA.

*Baseline patient characteristics* There were no age limits applied regarding patients. The following data on patient population were extracted: (1) number of patients included in the study and (2) analyzed in the final analysis; (3) age of patients (mean ± SD, median and/or range); (4) male-to-female ratio; (5) smoking (*n* + percentage); (6) diabetes mellitus (*n* + percentage); (7) hypertension (*n* + percentage); (8) dyslipidaemia (*n* + percentage); (9) renal failure (*n* + percentage); (10) coronary artery disease (*n* + percentage); (11) stroke history (*n* + percentage); (12) BMI \< 18,5 kg/m2 (*n* + percentage); (13) other factors (*n* + percentage); (14) other baseline characteristics such as ankle-brachial index (ABI), toe pressure (mean ± SD in mmHg), ankle pressure, TcPO2 (mean ± SD in mmHg), ulcer classification (*n* + percentage), Fontaine classification (III or IV), Rutherford classification (IV, V and VI) and other characteristics when cited; and (15) anticoagulation/antiplatelet medication at baseline (*n* + percentage).

*Procedure description* The following data were extracted: (1) who performed the procedure (interventional radiologist, vascular surgeon or other); (2) experience defined (number of procedures performed or years of experience); (3) which procedure was performed (only PTA (balloon), PTA + stent placement or other); and (4) if the study was described in sufficient detail to permit its replication (if information was provided as stated in previous items 1--3).

*Angiographic outcomes and complications* data were extracted on how articles defined (1) technical success; (2) partial success/failure; (3) complete technical failure; (4) major complications; and (5) minor complications and how many successes, failures and complications occurred.

*Follow-up and dropout patients* The following data were extracted regarding follow-up: (1) a summary of follow-up time and scheme; (2) if all patients underwent the same follow-up (yes or no) and (3) were dropout patients adequately reported (yes or no, with or without reasons for dropout or unclear).

*Clinical outcomes and predictive factors* Data were extracted on the three previously defined outcome variables: (1) ulcer healing; (2) AFS (major of minor) or limb salvage and (3) overall survival at baseline and at least 1-year follow-up with a maximum of 5-year follow-up. Data on predictive factors either in terms of regression analysis (univariate or multivariate) were extracted.

Data Analysis {#Sec7}
-------------

All data at baseline were presented as number plus percentage, with the exception of age, which is presented as a mean. Because standard deviation was not available in all datasets, result on baseline could not be pooled.

Data on ulcer healing, AFS and overall survival at baseline and at least 1-year follow-up were recorded. Data on predictive factors for ulcer healing, AFS (also limb salvage) and survival were extracted as reported in papers. As anticipated, the number of studies was limited. The data were heterogeneously presented so even meta-analysis with random effect approach would not be suitable for pooling predictive values. All data are therefore presented per study.

Results {#Sec8}
=======

Search, Selection and Inclusion of Relevant Articles {#Sec9}
----------------------------------------------------

The search yielded 1635 studies: 734 from Pubmed and 901 from EMBASE (see Appendix [1](#Sec29){ref-type="sec"}).

After excluding duplicates (240), letters/comments/editorials (57), conferences (354), case reports (42), other languages than English, Dutch, French or German (38), reviews and guidelines (228), study protocols (7), articles not involving CLI (37) and seven articles of which the full article could not be obtained, 625 articles on CLI remained.

Subsequently, articles were excluded based on title and abstract because they had less than 50 patients (136), they did not undergo PTA (152), were retrospective in nature (146) or had less than 1 year of follow-up (8) which yielded 183 potentially relevant articles. Full texts of these articles were checked on inclusion criteria: 173 articles did not meet the inclusion criteria and ten studies were included for data extraction (see Fig. [1](#Fig1){ref-type="fig"}) \[[@CR21]--[@CR30]\].Fig. 1Search, selection and inclusion of relevant articles. ^a^Patients did not undergo primary or standard PTA (e.g., use of primary stenting or drug eluting stent) or it was not clear what number of patients did undergo PTA. ^b^In several studies patients did undergo PTA; however, no data were separately mentioned from other procedures (e.g., bypass surgery)

Study Design Characteristics {#Sec10}
----------------------------

Of the ten articles included, all were cohort studies; most studies were performed based on prospective-designed databases and were single center. In all studies, there was no role of funders (see Table [1](#Tab1){ref-type="table"}).Table 1Study design characteristicsReferencesType of studyData collectionStudy design^a^Initiation institute, departmentRecruitment periodInstitutional review board approvalFunding receivedFunders role in study\[[@CR21]\]CohortProspective databaseMulticenterSurgeryJan 2000--Dec 2007Approved and requirement for IC waivedNoNo\[[@CR22]\]CohortProspectiveSingle centerRadiologyJul 2003--Dec 2007Approved and IC obtainedUnclearNo\[[@CR23]\]CohortProspective databaseSingle centerSurgery2007--2012ApprovedNoNo\[[@CR24]\]CohortProspectiveSingle centerSurgeryJan 1999--Jun 2004Approved and IC obtainedNoNo\[[@CR25]\]CohortProspective databaseSingle centerSurgeryFeb 2004--Feb 2012ApprovedNoNo\[[@CR26]\]CohortProspective databaseSingle centerSurgeryMar 2003--Sep 2010Approved and IC obtainedNoNo\[[@CR27]\]CohortProspective databaseMulticenterCardiologyApr 2004--Jun 2011UnclearNoNo\[[@CR28]\]CohortProspectiveMulticenterCardiovasular centerDec 2009--Jul 2011Approved and IC obtainedNoNo\[[@CR29]\]CohortProspectiveSingle centerRadiologyUnclearApproved and IC obtainedNoNo\[[@CR30]\]CohortProspective databaseSingle centerSurgeryApr 2010--Dec 2012UnclearNoNo^a^ We consider studies with authors from different centers as multicenter

Patient Selection {#Sec11}
-----------------

The patient selection was consecutive in most of the studies. In all studies, patients were included with CLI; however, the spectrum of patients was equivocal, as in one study only patients \> 80 years were included \[[@CR21]\], only diabetic patients \[[@CR22]\], only hemodialysis patients \[[@CR27]\] or patients with Rutherford V and VI \[[@CR28]\] (see Table [2](#Tab2){ref-type="table"}).Table 2Patient selection criteriaReferencesConsecutive sampleInclusion/exclusion criteriaSpectrum of patients representative\[[@CR21]\]ConsecutiveInclusion\
Patients with CLI (ischemic rest pain or tissue loss: ulceration or gangrene)\
Patients aged at least 80 years\
Patient who underwent PTANo, only patients \>80 years\[[@CR22]\]ConsecutiveInclusion\
Diabetic patients with Fontaine stage IV CLI, not suitable for surgical recanalization\
Patients undergoing infrainguinal subintimal angioplastyNo (only diabetic patients and stage IV CLI)\[[@CR23]\]UnclearInclusion\
Patients with CLI who underwent isolated intervention for tissue loss (Rutherford V and VI)\
Patient with end stage renal disease on hemodialysis compared to patients without ESRD (no-hemodialysis)No\[[@CR24]\]ConsecutiveInclusion\
All patients presenting with chronic CLI\
Definition of CLI: (1) presence of ischemic rest pain for \>2 weeks or ischemic tissue loss associated with (2) an absolute ankle pressure of \<50 mm Hg or great toe pressure of \<30 mm Hg\
Exclusion:\
Patients with acute limb ischemiaYes\[[@CR25]\]ConsecutiveInclusion\
Patients undergoing an attempt at infrapopliteal angioplasty for CLI or bypass graft outflow vessel stenosisYes\[[@CR26]\]Consecutive (stated as 'all patients')Inclusion\
All patients who underwent endovascular therapy for crural arteries (defined as arteries below the popliteal segment)\
Chronic CLI, defined as \>2 weeks of rest pain, ulcers, or tissue loss, attributed to arterial occlusive diseaseYes\[[@CR27]\]ConsecutiveInclusion\
Patients with hemodialysis who have CLI with ischemic wounds, who underwent EVT for isolated infrapopliteal lesions\
Exclusion\
Patients with CLI who underwent multilevel EVT due to tibial artery lesions combined with femoropopliteal (FP) lesions or aorto-iliac FP lesions\
CLI patients with functionally unsalvageable limbs with ischemic ulcer or gangrene spreading extensively past the ankle\
Patients with functional contraindications, including those bedridden without intractable ischemic pain\
Patients with psychiatric contraindications, including those with dementia or mental retardation from whom understanding of the treatment cannot be gained\
Patients with social contraindications for whom continuation of treatment would be difficult due to lack of cooperation from family members or nursesNo (only hemodialysis patients)\[[@CR28]\]ConsecutiveInclusion\
Patients with tissue loss (Rutherford class V or VI) caused by infrainguinal disease\
Available postprocedural skin perfusion pressure (SPP) and ankle-brachial index\
Clinical outcomes including 12-month AFS, freedom from major adverse events, defined as major amputation or any reintervention and complete wound healing\
Exclusion\
Previous major amputation\
Unsalvageable limb defined as extensive ischemic ulceration or gangrene beyond the transmetatarsal level that would eventually require major amputation after EVT\
Concurrent iliac artery disease\
CLI attributable to acute arterial occlusion or to non-atherosclerotic or inflammatory diseases\
CLI presenting with rest pain and no tissue loss (Rutherford IV)No (only Rutherford V and VI)\[[@CR29]\]UnclearInclusion\
CLI symptoms (Rutherford categories IV--VI)\
DSA documentation of infrapopliteal obstructive arterial disease\
Bail-out stenting after suboptimal and/or complicated below-knee angioplasty\
Reference diameter of native tibial vessel less than 4 mm\
Exclusion\
History of severe contrast allergy/hypersensitivity\
Hypersensitivity to aspirin and/or clopidogrel\
Systemic coagulopathy or hypercoagulation disorders\
Acute limb ischemia\
Buerger disease\
Deep vein thrombosis\
Bifurcation and/or trifurcation lesions\
Previous use of other drug eluting stent (not SES)\
Stenting indications after suboptimal and/or complicated balloon angioplasty\
Elastic recoil\
Flow-limiting dissection\
Residual stenosis more than 30%Yes\[[@CR30]\]ConsecutiveInclusion\
All patients with CLI who were not eligible for BTK reconstructive vascular surgeryYes

Baseline Patient Characteristics {#Sec12}
--------------------------------

In total, 2448 patients were included who were CLI patients and underwent PTA with or without bare metal stent placement. Mean ages ranged from 50 to 85.9 years. Male-to-female ratio was 816:534 in the seven studies mentioning this ratio \[[@CR21]--[@CR23], [@CR27]--[@CR30]\]. In addition, a broad range of risk factors was present: smoking rate from 6.9 to 58.3%, diabetes from 49.1 to 100%, hypertension from 51.6 to 98%, dyslipidaemia from 21.1 to 65% and renal disease up to 100%. Other risk factors such as coronary artery disease, cerebrovascular disease and stroke were also present in the majority of patients (see Table [3](#Tab3){ref-type="table"}). Table 3Patient baseline characteristics: risk factorsReferencesN of patient analyzedAge (years) Mean ± SD; median + rangeMale: femaleSmoking *N* (%)Diabetes mellitus *N* (%)Hypertension *N* (%)Dyslipidaemia *N* (%)Renal failure *N* (%)Coronary artery disease *N* (%)\[[@CR21]\]277 CLI patients who underwent PTA85.9 ± 4.077:20019 (6.9%)143 (51.6%)212 (51.6%)75 (27.1%)58 ± 21196 (70.8%)hyperlipidaemiaeGFR mean ± SD\[[@CR22]\]6069.4 ± 9.441:1935 (58.3%)60 (100%)25 (41.7%)Range 49--86Duration: 21.9 ± 12 yearsCardiac disease\[[@CR23]\] Non- hemodialysis group16450 ± 1382:8221 (13%)126 (77%)152 (93%)96 (59%)65 (40%)\[[@CR23]\] Hemodialysis group7866 ± 1244:3415 (20%)68 (88%)76 (98%)51 (65%)78 (100%)33 (43%)\[[@CR24]\]207 patients who underwent PTA77.1 ± 9.7119 (57.5%)\[[@CR25]\]459 limbs in 413 patients71 ± 12271:188 (limbs)203 (58%)342 limbs (75%)386 (84%)279 (61%)71 (15%) Dialysis dependent229 (50%)Range 31--96Serum creat \>2: 102 (22%)\[[@CR26]\]527 limbs in 478 patients73.9 ± 0.53315:212 (limbs)62 (12%)256 limbs (49.1%)344 limbs (70%)Dialysis dependent limbs: 38 (7.4%)228 limbs (45%)Creat \>150: 39 (8%)\[[@CR27]\] Minor tissue loss group340 patients with minor tissue loss69.2 ± 9.6265:75112 (32.9%)260 (76.5%)244 (71.8%)79 (23.2%)340 (100%)198 (58.2%)\[[@CR27]\] Major tissue loss group109 with major tissue loss66.5 ± 10.485:2447 (43.1%)82 (75.2%)83 (76.1%)23 (21.1%)109 (100%)63 (57.8%)\[[@CR28]\]21173.6 ± 9.7134:77Past 87 (41%)152 (72%)166 (79%)72 (34%)129 (62%)100 (47%)Dialysis: 111 (53%)Current 19 (9%)\[[@CR29]\]41 (only bare metal stent (BMS))71.55 ± 8.2737:421 (51.2%)31 (75.6%)32 (78.0%)28 (68.3%)17 (41.5%) Renal disease19 (46.3%)Insulin dependent 14 (45.2%)Hyperlipidaemiacardiac disease\[[@CR30]\]7072 Range 43--9351:1938 (54%) history of smoking50 (71%)44 (63%)38 (40%) cardiac diseaseReferencesStroke history *N* (%)Other risk factors *N* (%)\[[@CR21]\]61 (22.0%)Pulmonary disease: 46 (16.6%)Cerebrovascular disease\[[@CR22]\]15 (25%)Cholesterol: 161.4 ± 25.5 mg/dl (range 81--246)Cerebrovascular diseaseCreatinine: 1.3 ± 1.1 mg/dl (range 0.5--7.5)Previous peripheral intervention: 12 (20%)Retinopathy: 35 (58.3%)\[[@CR23]\] Non- hemodialysis group36 (22%)Metabolic syndrome: 110 (67%)Cerebrovascular diseaseHypothyroidism: 26 (16%)\[[@CR23]\] Hemodialysis group19 (24%)Metabolic syndrome: 46 (59%)Hypothyroidism: 10 (13%)\[[@CR24]\]\[[@CR25]\]74 (16%)Congestive heart failure: 120 (26%)COPD: 37 (8%)\[[@CR26]\]69 limbs (14%)\>80 years 225 limbs (38.33%)\[[@CR27]\] Minor tissue loss group88 (25.9%)Hemodialysis: 340 (100%)Cerebrovascular diseaseCRP \> 5.0 mg/dl: 56 (16.6%)COPD: 26 (7.7%)\[[@CR27]\] Major tissue loss group31 (28.4%)Hemodialysis: 109 (100%)CRP \> 5.0 mg/dl: 37 (33.9%)COPD: 12 (6.8%)\[[@CR28]\]47 (22%)BMI \< 18.5%: 22.0 ± 3.4 (*n* = 207)Serum albumin: 3.6 ± 0.5 (n-197)HbA1C: 6.2 ± 1.2 (*n* = 198)Anemia: 150 (71%)Heart Failure: 62 (30%)Previous myocardial infarction: 37 (18%)\[[@CR29]\]\[[@CR30]\]COPD: 10 (14%)

ABI was mentioned in only small number of studies, other measurements such as toe pressure and ankle pressure were only mentioned in the study of Strom et al. (toe pressure mean 30 mmHg \[range 0--60 mmHg\] and ankle pressure mean 50 mmHg \[range 0--60 mmHg\]) \[[@CR30]\]. The TcPO2 was not mentioned in any of the studies. The disease severity in terms of Fontaine classification or Rutherford category was described heterogeneously (see Table [4](#Tab4){ref-type="table"}). Table 4Patient baseline characteristics: risk factors, continuing Table [3](#Tab3){ref-type="table"}ReferencesAnkle-brachial index (ABI) Mean ± SD; median + rangeFontaine classification, Rutherford category or other classificationAnticoagulation/antiplatelet medication at baseline (N and percentage)\[[@CR21]\]NAFontaine III: 47 (17%)NAFontaine IV: 230 (83%)\[[@CR22]\]Fontaine IV: 60 (100%)NATASC B: 9 (15%)TASC C: 24 (40%)TASC D: 27 (45%)\[[@CR23]\] Non-hemodialysis groupRutherford V: 139 (85%)Aspirin and Heparin: 164 (100%)Rutherford VI: 25 (15%)\[[@CR23]\] Hemodialysis groupRutherford V: 48 (62%)Aspirin and Heparin: 78 (100%)Rutherford VI: 30 (38%)\[[@CR24]\]0.45 (0.15--1.47)Rutherford IV: 30 (14.5%)Rutherford V: 175 (84.5%)Rutherford VI: 2 (1%)\[[@CR25]\]Tissue loss 363 (79%)Aspirin: 63Rest pain 57 (12%)Clopidogrel: 32Warfarin: 20Acute limb ischemia 10 (3%)Threatened graft 28 (6%)TASC A 75 (16%)TASC B 101 (22%)TASC C 126 (27%)TASC D 157 (34%)\[[@CR26]\]Rutherford IV: 158 limbs (30%)Rutherford V and VI: 358 limbs (67.9%)\[[@CR27]\]0.57 ± 0.24Ulcer classification: infected 119 (35.0%)All patients Aspirin 100 mg/day and Clopidogrel 75 mg/day. Cilostazol 200 mg/day at and after procedure\[[@CR27]\]0.59 ± 0.21Ulcer classification: infected 74 (67.9%)All patient Aspirin 100 mg/day and Clopidogrel 75 mg/day. Cilostazol 200 mg/day at and after procedure\[[@CR28]\]0.72 ± 0.23 (*n* = 180)Ulcer classification: wound infection 34 (16%)Aspirin: 184 (87%)Rutherford V: 173 (82%)Cilostazol: 107 (51%)Clopidogrel: 94 (45%)Rutherford VI: 38 (18%)\[[@CR29]\]Fontaine III/Rutherford IV: 15 (36.6%)All patients Aspirin 100 mg/day and Clopidogrel 75 mg/day 3 days before procedureFontaine III/Rutherford V: 16 (39.0%)Fontaine IV/Rutherford VI: 10 (24.4%)\[[@CR30]\]NAUlcer classification: ischemic ulcers 59 (84%)All patients Acetylsalicylic acid (ASA) 75 mg daily after the procedureClopidogrel postoperatively in selected cases (n = 4)

Procedure Description, Outcomes and Complications {#Sec13}
-------------------------------------------------

In most studies, it was not clear who performed the procedure. Moreover, the experience of the operator was not defined in any of the studies. In none of the studies, the procedure was described in sufficient detail to replicate. The angiographic outcome in terms of technical success was defined well, and complications were reported in detail.

All data on procedure description and outcomes are given in detail in Table [5](#Tab5){ref-type="table"}.Table 5Description of angiographic procedures, angiographic outcomes and complicationReferencesDescription of angiographyAngiographic outcomes and complicationsWho performed procedureExperienceType of procedureProcedure description in sufficient detail to replicateDefinitions outcomes (definitions and number)Complications (definitions and number)\[[@CR21]\]UnclearUnclear-PTA\
-Stent placement in case of dissection or a long lesionNoNANA\[[@CR22]\]Interventional radiologistUnclear-PTANo-Technical success: visualization of a correctly dilated subintimal lumen, with adequate run-in and run-off vessels, without immediate complications: 91.7% (55/60)-Procedure: 1 dissection treated by stenting, 1 hematoma at re-entry site, 1 pseudoaneurysm, 1 retroperitoneal hematoma; all treated conservatively\
-Peri-procedural mortality 5% (3 patients): myocardial infarction in 2 cases and renal failure in 1 patient\[[@CR23]\] Non-hemodialysis groupUnclearUnclear-PTA\
-Stent placement primarily or in case of flow-limiting dissections, intimal flaps or poor technical results\
-Atherectomy (Limited number)No-Technical success: a patient target tibial vessel with successful revascularization of the intended angiosome or inline flow across the ankle into the foot\
-Technical failure: 4% (6/164)-Major complication was defined as any event, regardless of how minimal, not routinely observed after endoluminal therapy that required treatment with a therapeutic intervention or rehospitalisation within 30 days of procedure. Systemic complications were sepsis, related to cardiac, pulmonary or renal system. Local complications were related to access site, surgical wounds and the treated limb: 1% (1/164) systemic and 0% (0/164) local complications\
-Lesion complications (site of intervention): 2% (3/164)\
-Death \< 30 days of procedure was considered procedure-related and a perioperative death: 0%\[[@CR23]\] Hemodialysis groupUnclearUnclear-PTA\
-Stent placement primarily or in case of flow-limiting dissections, intimal flaps or poor technical results\
-Atherectomy (Limited number)No-Technical success: a patent target tibial vessel with successful revascularization of the intended angiosome or inline flow across the ankle into the foot\
-Technical failure: 2% (2/78)-Major complication was defined as any event, regardless of how minimal, not routinely observed after endoluminal therapy that required treatment with a therapeutic intervention or rehospitalisation within 30 days of procedure. Systemic complications were sepsis, related to cardiac, pulmonary or renal system. Local complications were related to access site, surgical wounds and the treated limb: 4% (3/78) systemic and 1% (1/78) local complications\
-Lesion complications (site of intervention): 10% (8/78)\
-Death \< 30 days of procedure was considered procedure-related and a perioperative death: 2% (*n* = 2)\[[@CR24]\]UnclearUnclear-PTA (with or without stenting)No-Primary technical success 196/207 (94.7%)\
-Repeat target extremity revascularizations: re-PTA in 54/207 limbs, reconstructive surgery in 26/207 limbsNA\[[@CR25]\]UnclearUnclear-PTA (with or without stent placement)\
-Atherectomy in 6 patientsNo-Technical success defined as a residual stenosis \<30%: 427/459 (93%)Intraprocedural complications: flow-limiting dissections 69 (15%), vessel spasm 29 (6%), arteriovenous fistulas 6 (1%), distal embolization 17 (4%), rupture 1 (0.2%)\
Postoperative complications: access site arterial injury 20 (4%), acute kidney injury 11 (2%), acute myocardial infarction 4 (1%), congestive heart failure 4 (1%), dysrhythmia 5 (1%), respiratory failure or pneumonia 5 (1%), gastro-intestinal bleed/hematemesis 5 (1%), cerebrovascular accident 3 (1%)\
In-hospital mortality: 11 patients (2%)\
30-day mortality: 26 (6%)\[[@CR26]\]Interventional radiologistUnclear-PTANoSuccessful if direct flow was restored in the treated vessel with less than 30% residual stenosis: number NAComplications: embolus 17 (2.9%), groin hematoma 16 (2.7%), target vessel thrombosis 14 (2.4%), vessel perforation 9 (1.5%), vessel rupture 7 (1.2%), deterioration in ischemia 2 (0.3%), flow-limiting dissection 1 (0.2%), arteriovenous fistula 1 (0.2%), retroperitoneal hemorrhage 1 (0.2%), others 8 (1.4%)\[[@CR27]\] (minor tissue loss group and major tissue loss group)Cardiovascular interventionalist or vascular surgeonUnclear-PTANoTechnical success was defined as achieving a degree of residual stenosis \< 30% at the target lesion site and achieving straight-line flow from the aorta down to either a patent dorsalis pedis or plantar artery: 241/340 (70.9%) in minor tissue loss group. 77/109 (70.6%) in major tissue loss group (*p* = 0.961)Perioperative mortality 9/340 (2.6%) in minor tissue loss group; 3/109 (2.8%) in major tissue loss group\[[@CR28]\]UnclearUnclear-Below the knee: PTA (plain angioplasty or cutting balloon)\
-Femoral lesions: PTA (plain angioplasty or cutting balloon) or nitinol stent placementNoTechnical success was defined as straight flow to the foot: 197/211 (93%)NA\[[@CR29]\] (only the bare metal stent group)UnclearUnclear-BMS placementNoTechnical success was defined as recanalization of at least one straight-line of blood flow to the distal foot: 93.6%-Retroperitoneal hemorrhage: 1, self-limiting\
-30-day mortality rate: 1\[[@CR30]\]Vascular surgeonUnclear-PTA (with or without stent placement)NoNAOne patient (2%) developed a groin hematoma demanding surgical evacuation\
One patient (2%) presented with acute abdomen and respiratory distress suspected of acute mesenteric ischemia\
Two patients died within 30 days (perioperative mortality; 3%) due to toxicity awaiting amputation (*n* = 1) and cerebral hemorrhage occurring after a minor amputation (n = 1)

Follow-Up and Dropout Patients {#Sec14}
------------------------------

The follow-up was not homogeneous, but in general 1 month, 3-, 6- and 12-month follow-up was done. Patients did not undergo the same follow-up in seven studies, while in three studies patients did undergo the same follow-up. Dropout rates are poorly reported. Only one study \[[@CR24]\] accurately reported dropouts, with missing baseline information as most frequent reason for dropout. Follow-up ranged from less than 1 month up to 109 months. All details are given in Table [6](#Tab6){ref-type="table"}.Table 6Follow-up and dropouts of patientsReferencesSummarize follow-up time and schemeUndergo same follow-upDropouts reported\[[@CR21]\]1, 6 and 12 months and annually thereafterNo: mean 2,0 yearsStudy registry, dropouts not reported\[[@CR22]\]Not statedNo: range 1--48 months, 22.8 ± 14.9, median 22.5 monthsNone\[[@CR23]\] Non-hemodialysis and hemodialysis group1, 3 and every 6 months following their procedureNo: means or ranges statedStudy registry, dropouts not reported\[[@CR24]\]2, 6 and 12 monthsYesYes (missing baseline information (10), refusal to undergo vascular imaging (2), withdrawal of informed consent (1), lack of follow-up data (5)\[[@CR25]\]2 weeks, then every 3 months for 1 year and every 6 months thereafterNo: average 15 months (range 0--85 months)Early deaths reported. Dropouts in further follow-up are not stated\[[@CR26]\]1, 6, 12, 36 monthsNo: mean 26.9 ± 0.54 months, median 40 months with a maximum of 109 monthsNo\[[@CR26]\]1, 3, 6 months and every 3 months thereafter up to 3 yearsYesNone\[[@CR28]\]1, 3, 6, 12 monthsYesNone\[[@CR29]\]1, 3, 6, 12 months and yearly thereafterNo: mean 17.15 months ± 1.73, range 0.7--36 monthsNo\[[@CR30]\]6 weeks and 1 year (no standard FU after 1 year)No: median 20 months (range 0--41 months)None

Clinical Outcomes: Ulcer Healing, AFS/Limb Salvage and Survival {#Sec15}
---------------------------------------------------------------

### Ulcer Healing {#Sec16}

In three studies \[[@CR22], [@CR25], [@CR28]\], data on ulcer healing were given. It seems that complete healing can be achieved in most of the patients within 1 year \[[@CR25], [@CR28]\]. Details are given in Table [7](#Tab7){ref-type="table"}. Table 7Follow-up data on ulcer healingReferences6 months1 year3 year\[[@CR22]\]Healing 45 (75%)Improved 7 (11.6%)Stable 4 (6.7%) (Data at latest FU, however, FU ranges from 1 to 48 months)\[[@CR25]\]*N* = 361*N* = 192Complete healing 15%Complete healing 63%Improved 30%Improved 55%Stable 27%Stable 8%Worse 2%Worse 0.5%\[[@CR28]\]*N* = 16487%

AFS or Limb Salvage {#Sec17}
-------------------

In all studies \[[@CR21]--[@CR30]\], data on AFS or limb salvage were given. One-year AFS ranged from 49.5 to 75.2%, 2-year AFS from 37 to 58% and 3-year AFS from 22 to 59%. The limb salvage rates for 1 month, 1 year, 2 year and 3 year range from 95 to 97.4%, 71 to 95%, 54 to 93.3% and 32 to 92.7%, respectively. All data are given in Table [8](#Tab8){ref-type="table"}.Table 8Follow-up data on AFS or limb salvageReferences1 month1 year2 years3 years4 years5 yearsAFS (Amputation free survival) \[[@CR21]\]93.1%62.4%53.0%44.3%35.3%32.9% \[[@CR23]\] Non-hemodialysis group54 ± 4% \[[@CR23]\] Hemodialysis group22 ± 9% \[[@CR26]\]75.2%59.0% \[[@CR26]\] Minor tissue loss group63.5 ± 2.9%51.0 ± 3.3%44.1 ± 3.7% \[[@CR26]\] Major tissue loss group49.5 ± 5.5%37.0 ± 6.1%29.1 ± 7.0% \[[@CR28]\]73.9% \[[@CR30]\]68%58%Limb salvage \[[@CR21]\]97.4%88.8%85.4%82.6%80.2%78.3% \[[@CR22]\]95% (3 patients, 5% above knee amputation)95%93.3% \[[@CR23]\] Non-hemodialysis group76 ± 3%74 ± 4%69 ± 4% \[[@CR23]\] Hemodialysis group71 ± 5%54 ± 7%32 ± 8% \[[@CR24]\]96.5%81% \[[@CR25]\]96%84%81% \[[@CR26]\]92.7% \[[@CR26]\] Minor tissue loss group87.4 ± 1.8%84.4 ± 2.1%83.7 ± 2.2% \[[@CR26]\] Major tissue loss group73.9 ± 4.3%71.2 ± 4.5%71.2 ± 4.5% \[[@CR29]\]80.3%

### Survival {#Sec18}

Survival rates were described in nine studies \[[@CR21]--[@CR29]\] with at least 3-year follow-up in most of the studies (see Table [9](#Tab9){ref-type="table"}). The survival rates for 1 month, 1 year, 2 years and 3 years range from 94 to 100%, 65.4 to 91.5%, 45.7 to 76% and 37.3 to 83.1%, respectively.Table 9Follow-up data on survivalReferences1 month1 year2 years3 years4 years5 years\[[@CR21]\]94.9%66.7%57.7%50.4%42.3%39.9%\[[@CR22]\]95%91.5%83.1%\[[@CR23]\] Non-hemodialysis group100%83 ± 3%76 ± 3%67 ± 4%\[[@CR23]\] Hemodialysis group98%70 ± 6%53 ± 7%45 ± 8%\[[@CR24]\]94%70.6%\[[@CR25]\]83%64%49%\[[@CR26]\]97.2%82.9%62.4%\[[@CR26]\] Minor tissue loss group74.9 ± 2.6%63.7 ± 3.2%54.0 ± 3.7%\[[@CR26]\] Major tissue loss group65.4 ± 5.2%45.7 ± 6.4%37.3 ± 7.7%\[[@CR28]\]80.6%\[[@CR29]\]70.7%\[[@CR30]\] Non-amputated group97%81%\[[@CR30]\] Amputated group64%

Predictive Factors {#Sec19}
------------------

When data were available on predictive values, these data were also extracted (see Table [10](#Tab10){ref-type="table"}). However, these data were presented heterogeneously. We extracted all data as given in the studies. In general for univariate analysis, data were given either (1) at a time point (e.g., AFS at 2 years) by Fisher exact test or Chi-square test (2 × 2 tables) or Student's *t* test (continuous normally distributed data) or Mann--Whitney tests (continuous not normally distributed data) or by association tests (continuous data) or (2) as time dependent by Kaplan--Meier analysis (with log rank test, for binary data) or Cox regression analysis (for multinomial or continuous data). Finally, multivariate analysis in either stepwise multiple regression analysis was used (at one time point) or Cox proportional regression analysis (for time dependent data) was performed.Table 10Prediction factors by outcomeReferencesFactors found to be significant in univariate analysisFactors predictive (with p-values)*Ulcer healing*\[[@CR22]\][Univariate analysis by fisher exact test, Chi-square test, Student's t test]{.ul}(*[p]{.ul}* [ \< 0.05]{.ul})[Stepwise multiple logistic regression]{.ul}Diabetes duration (*p* = 0.05)HbA1c (*p* = 0.001)HbA1c (*p* = 0.002)Serum creatinine levels (*p* = 0.03)Creatinine (*p* = 0.04)Site of recent canalization (*p* = 0.03)\[[@CR28]\][Univariate analysis, logistic regressionNot available]{.ul}Skin perfusion pressure (*p* = 0.022)Ankle-brachial Index (*p* \> 0.05)*AFS or limb salvage*\[[@CR21]\]^a^[Univariate analysis by fisher exact test, Chi-square, Mann--Whitney U test and Kaplan--Meier method]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Cox regression with backward selection]{.ul}AFS at 2 yearsAge (*p* \< 0.004)AFS decreased for increased age, decreased EGR, diabetes, coronary artery disease and bypass surgeryEGFR (*p* = 0.015)Diabetes (*p* = 0.003)Coronary artery disease (*p* = 0.004)Foot gangrene (*p* = 0.025)Level of vascularization (*p* = 0.004)Technique of revascularization (*p* = 0.005)\[[@CR23]\][Univariate analysis in Kaplan--Meier and log rank or associations]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Cox proportional regression analysis]{.ul}Limb salvage (only hemodialysis group)Improvements in hemodynamics after intervention (*p* = 0.02)Improvements in hemodynamics after intervention (*p* = 0.009)Improvement in symptoms (*p* = 0.02)Improvement in symptoms (*p* \< 0.001)\[[@CR23]\] AFS (only hemodialysis group)[Univariate analysis in Kaplan--Meier and log rank or associations]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Cox proportional regression analysis]{.ul}Presence of hyperlipidemia (*p* = 0.006)MACE (*p* = 0.005)Cerebrovascular disease (*p* = 0.008)Metabolic syndrome (*p* = 0.02)Diabetes (*p* \< 0.001)Metabolic syndrome (*p* \< 0.001)Modified cardiac risk (*p* = 0.02)High-risk group (*p* = 0.04)Presence of MACE (*p* = 0.02)Elevated Finn score (*p* = 0.03)\[[@CR24]\][Not availableCox proportional regression analysis]{.ul}Limb salvageAdvanced ageDiabetes\[[@CR25]\][Univariate analysis using Kaplan--Meier and log rank]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Cox proportional regression analysis]{.ul}Limb salvageTASC class (*p* = 0.006)TASC class (*p* = 0.031)Not being a candidate for bypass (*p* \< 0.001)Not being a candidate for bypass (*p* \< 0.001)Dialysis (*p* \< 0.001)Serum \> 2.0 mg/dl (*p* = 0.02)\[[@CR26]\][Univariate analysis by Fisher exact test]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Not available]{.ul}AFS at 1 yearCoronary artery disease (*p* \< 0.001)Rutherford category (*p* \< 0.001)Renal disease (*p* = 0.030)\[[@CR26]\][Univariate analysis by Fisher exact test]{.ul}(*[p]{.ul}* [ \< 0.05]{.ul})[Not available]{.ul}AFS at 3 yearAge \< 60 (*p* = 0.015)Coronary artery disease (*p* \< 0.001)Rutherford category (*p* \< 0.001)Diabetes (*p* \< 0.003)Renal disease (*p* = 0.001)\[[@CR26]\][Univariate analysis by Fisher exact test]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Not available]{.ul}Limb salvageRutherford category (*p* = 0.016)Diabetes (*P* = 0.020)\[[@CR26]\][Univariate analysis, Kaplan--Meier method and log rank]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Cox proportional regression analysis]{.ul}Major amputation (Minor tissue loss group)Age \< 60 (*p* = 0.003)Age \< 60 (*p* = 0.014)Nonambulatory (*p* = 0.036)HbA1c ≥ 6.8% (*p* = 0.026)Hyperlipidemia (*p* = 0.027)C-reactive protein \> 5.0 mg/dl (*p* \< 0.001)HbA1c ≥ 6.8% (*p* \< 0.001)Albumin \< 3.0 g/dl (*p* = 0.007)C-reactive protein \> 5.0 mg/dl (*p* \< 0.001)Albumin \< 3.0 g/dl (*p* \< 0.001)Achieving technical success (*p* = 0.049)\[[@CR26]\][Univariate analysis, Kaplan--Meier method and log rank]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Cox proportional regression analysis]{.ul}Major amputation (Major tissue loss group)Nonambulatory (*p* \< 0.001)Nonambulatory (*p* \< 0.001)Heel location (*p* = 0.05)Calcified lesions (*p* = 0.029)Calcified lesions (*p* = 0.048)\[[@CR28]\][Univariate analysis, logistic regressionNot available]{.ul}AFS at 1 yearSkin perfusion pressure (*p* = 0.018)Ankle-brachial index (*p* \> 0.05)\[[@CR29]\]^b^ Limb salvageNot availableCox proportional regression analysisNo factors identified (tested)\[[@CR30]\] Overall amputation or major amputation[Univariate analysis by Fisher exact test]{.ul}(*[p]{.ul}* [ \< 0.05]{.ul})[Not available]{.ul}None of the factors tested was significant*Surviva*l\[[@CR22]\][Univariate analysis by fisher exact test, Chi-square test, Student's t test and Kaplan--Meier and log rank]{.ul}(*[p]{.ul}* [ \< 0.05]{.ul})[Cox proportional regression analysis]{.ul}SurvivalAge (*p* = 0.002)Age (*p* = 0.0001)Creatinine (*p* = 0.004)Ulcer healing (*p* = 0.03)Ulcer healing (*p* = 0.008)\[[@CR23]\][Univariate analysis in Kaplan--Meier and log rank or associations]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Cox proportional regression analysis]{.ul}Survival (only hemodialysis group)Cerebrovascular disease (*p* = 0.014)Presence of MACE (*p* = 0.04)Diabetes (*p* = 0.003)Major limb loss (*p* = 0.04)Presence of hyperlipidemia (*p* = 0.04)Presence of MACE (*p* = 0.005)Major limb loss (*p* = 0.008)\[[@CR25]\][Univariate analysis using Kaplan--Meier and log rank]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Cox proportional regression analysis]{.ul}SurvivalFactors not givenAge 71--80 years (*p* = 0.042)Age \> 80 (*p* \< 0.001)Serum creat \> 2.0 mg/dl (*p* = 0.038)Congestive heart failure (p = 0.04)Not being a candidate for bypass (p = 0.002)\[[@CR26]\][Univariate analysis by Fisher exact test]{.ul} (*[p]{.ul}* [ \< 0.05]{.ul})[Not available]{.ul}Survival at 3 yearAge (*p* = 0.003)Coronary artery disease (*p* \< 0.001)Rutherford category (*p* \< 0.001)Diabetes (*p* = 0.007)Renal disease (*p* = 0.005)\[[@CR29]\]\*\*[Not availableCox proportional regression analysis]{.ul}SurvivalNo factors identified (tested)\[[@CR30]\][Univariate analysis by Fisher exact test]{.ul}(*[p]{.ul}* [ \< 0.05]{.ul})[Not available]{.ul}(Death \< 1 year)None of the factors tested was significant^a^ In this study, although data (ulcer healing, AFS or survival) were reported separately for PTA, data of regression analysis was presented combined both groups: PTA and bypass surgery^b^ In this study, although data (ulcer healing, AFS or survival) were reported separately for PTA with Bare Metal Stent (BMS), data of regression analysis was presented for both PTA with BMS and PTA with drug eluting stent. The cox regression showed no difference between both groups Table 11Details search strategySearch termsNumber of hits*PUBMED*\#1Search "Critical limb ischemia OR critical limb ischemia"4246\#2Search (angioplasty OR endovascular revascularization OR percutaneous intentional extraluminal revascularization OR subintimal OR endovascular therapy)95,820\#3Search (major amputation OR amputation free survival OR death OR ulcer healing OR wound healing OR mortality OR survival)2,061,511\#4Search (\#1 AND \#2 AND \#3)915\#5Search (\#1 AND \#2 AND \#3) Sort by: Relevance Filters: published between January 2006 and April 2017; Humans734*EMBASE*\#1critical limb ischemia.mp. OR \*critical limb ischemia2669\#2\*percutaneous transluminal angioplasty balloon/ or \*percutaneous transluminal angioplasty/ or \*angioplasty72,918\#3\*Stent/ or \*revascularization149,863\#4\*mortality812,936\#5\*amputation/ or major amputation.mp. or \*leg amputation47,732\#6\*Ulcer healing or \*wound healing132,836\#7\*Survival770,209**\#8**\#1 AND (\#2 OR \#3) AND (\#4 OR \#5 OR \#6 OR \#7) published between January 2006 and April 2017901

### Predictive Factors in Ulcer Healing {#Sec20}

Number of studies reporting predictive factors is limited \[[@CR22], [@CR28]\] with different predictive factors (see Table [10](#Tab10){ref-type="table"}).

### Predictive Factors in AFS or Limb Salvage {#Sec21}

Predictive factors for AFS or limb salvage were reported in nine studies \[[@CR21], [@CR23]--[@CR30]\]. All studies had different univariate and multivariate outcomes; however, age and diabetes were found to be significant predictors in at least three studies \[[@CR21], [@CR23], [@CR24], [@CR27]\]. See details in Table [10](#Tab10){ref-type="table"}.

### Predictive Factors in Survival Analysis {#Sec22}

Also for the survival analysis, different predictive factors were found; however, age was found in 2 \[[@CR22], [@CR25]\] out of 5 studies reporting on predictive factors (see Table [10](#Tab10){ref-type="table"}). Based on these findings, age and diabetes should be at least taken into account when searching for predictive factors.

Discussion {#Sec23}
==========

Summary {#Sec24}
-------

In this review, we summarized the findings on predictive factors for wound healing, AFS and survival in CLI patients who underwent a PTA. As stated, the data were heterogeneously reported and presented. In addition, none of the studies found the same predictive factors. However, in several studies age and diabetes were found as predictive factors for AFS or limb salvage and survival. Several univariate studies showed age and diabetes as predictors \[[@CR12], [@CR31]--[@CR33]\].

Compared with Other Studies {#Sec25}
---------------------------

To our knowledge, no such systematic review has been published. There is a review \[[@CR34]\] in which the authors summarized risk stratification models for CLI with a summary of the respective strengths and limitations of each. These models were developed from prospective cohorts to identify and quantify variables that can subsequently predict outcome in individual patients. In the prospective cohort, treatment options generally were compared (e.g., open and endovascular therapies) and new therapeutics were evaluated. The outcomes were not specific for defining risk models in patients with CLI patients undergoing PTA.

Strength of this Review {#Sec26}
-----------------------

The major strength of our study is that we focussed on patients with CLI who underwent PTA to identify possible predictive factors for clinically relevant outcomes. We have done this to create a homogeneous and clinically relevant population, in order to draw conclusions.

We included studies which aimed to study predictive values of all types of risk factors. In addition, we only selected prospective studies or studies that used a prospective database, to have a predefined design without missing a lot of data. It is known that missing data are much more common in retrospective studies, in which routinely collected data are subsequently used for a different purpose \[[@CR35]\].

Limitations of this Review {#Sec27}
--------------------------

Although all studies were performed prospectively or a prospective database was present with a spectrum of patients which are represented, the data were presented too heterogeneously. Even the AFS or survival analysis was not reported homogeneously. The presented data on the predictive values varied even more, making general conclusions difficult.

Conclusion and Recommendations {#Sec28}
------------------------------

It is not clear which risk factors should be taken into account. However, in several studies two factors, age and diabetes, were found as predictive factors for AFS or limb salvage and survival in patients with CLI undergoing PTA. Therefore, we believe that these factors should be taken into account in the future when searching for predictive factors and when analyzing study data on endovascular treatments for CLI. More research on this topic is needed. A trial with registry of all risk factors and the outcomes up to 12 months would be very important. Future research is needed to simplify and improve the accuracy and generalizability of risk stratification in CLI.

Appendix 1 {#Sec29}
==========

See Table [11](#Tab10){ref-type="table"}.
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